Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

Bonney, Glenn Kunnath; Chew, C. K.; Lodge, Peter; Hubbard, Joleen M.; Halazun, Karim J.; Trunečka, Pavel; Muiesan, Paolo; Mirza, Darius F.; Isaac, John; Laing, Richard W.; Iyer, Shridhar Ganpathi; Chee, Cheng Ean; Yong, Wei Peng; Muthiah, Mark; Panaro, Fabrizio; Sanabria, Juan; Grothey, Axel; Moodley, Keymanthri; Chau, Ian; Chan, Albert; Wang, Chih Chi; Menon, Krishna; Sapisochín, Gonzalo; Hagness, Morten; Dueland, Svein; Line, Pål–Dag; Adam, René

doi:10.1016/s2468-1253(21)00219-3

Cited by 80 publications

(55 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…A recent consensus guideline was published by the International Hepato-Pancreato-Biliary Association (IHPBA), identifying that patients with non-resectable CRLM without extrahepatic metastatic disease or high-risk molecular criteria (BRAF V600E mutation, microsatellite stable, and mismatch repair proficient) who have shown a response to either 3 months of chemotherapy or 6 months of bridging therapy may be eligible for LT [ 20 ]. The importance of appropriate patient selection was also emphasized in these guidelines [ 20 ]. To improve consistency in referral patterns, evaluations of resectability, and management decisions for patients with CRLM, ongoing education, discussions, and development of consensus guidelines should be strived for both at the local and societal level [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey

et al. 2022

Self Cite

View full text Add to dashboard Cite

Up to 50% of colorectal cancer (CRC) patients develop colorectal liver metastases (CRLM). The aim of this study was to gauge the awareness and perception of liver transplantation (LT) for non-resectable CRLM, and to describe the current referral patterns and management strategies for CRLM in Canada. Surgeons who provide care for patients with CRC were invited to an online survey through the Canadian Association of General Surgeons, the Canadian Society of Colon and Rectal Surgeons, and the Canadian Society of Surgical Oncology. Thirty-seven surveys were included. The most utilized management strategy for CRLM was to refer to a hepatobiliary surgeon for assessment of metastectomy (78%), and/or refer to medical oncologists for consideration of chemotherapy (73%). Among the respondents, 84% reported that their level of knowledge about LT for CRLM was low, yet the perception of exploring the option of LT for non-resectable CRLM seemed generally favorable (81%). The decision to refer for consideration of LT for CRLM treatment seemed to depend on patient-specific factors and the local hepatobiliary surgeon’s recommendation. Providing CRC care providers with educational materials on up-to-date CRLM management may help raise the awareness of the use of LT for non-resectable CRLM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, the use of ICIs in a neoadjuvant setting is of significant interest to the field of HCC and transplant oncology. Clinical trials (NCT 04,035,876 and NCT 04425226) [ 77 , 78 ] are currently underway and will provide some insights on the safety profile and efficacy of ICI use in this setting.…”

Section: Discussionmentioning

confidence: 99%

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors

Gao

Anwar

Abraham

et al. 2021

Cancers

View full text Add to dashboard Cite

Liver transplantation offers excellent outcomes for patients with HCC. For those who initially present within the Milan criteria, bridging therapy is essential to control disease while awaiting liver transplant. For those who present beyond the Milan criteria, a liver transplant may still be considered following successful downstaging. Since the introduction of atezolizumab as part of the first-line treatment for HCC in 2020, there has been increasing interest in the use of ICIs as bridging or downstaging therapies prior to liver transplant. A total of six case reports/series have been published on this topic, with mixed outcomes. Overall, liver transplantation can be performed safely following prolonged ICI use, though ICIs may increase the risk of fulminant acute rejection early in the post-operative period. A minimal washout period between the last dose of ICI and liver transplantation has been identified as an important factor predicting transplant outcomes; however, further research is needed.

show abstract

“…In accordance with the ethical principle of utility, which incorporates beneficence and non-maleficence, this stringent patient selection process aims to identify patients with non-resectable colorectal liver metastases who would derive the most survival benefit from liver transplantation. Nonetheless, the inclusion of patients with malignant indications in transplantation list will cause tension to the principles of utility and justice, which is recognized by theLT-CoMet 21 working group [ 236 ].…”

Section: Emerging Technologies and Future Directionsmentioning

confidence: 99%

Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist

Torres-Jiménez

Esteban-Villarrubia

Ferreiro-Monteagudo

et al. 2021

Cancers

View full text Add to dashboard Cite

For patients with isolated liver metastases from colorectal cancer who are not candidates for potentially curative resections, non-surgical local treatments may be useful. Non-surgical local treatments are classified according to how the treatment is administered. Local treatments are applied directly on hepatic parenchyma, such as radiofrequency, microwave hyperthermia and cryotherapy. Locoregional therapies are delivered through the hepatic artery, such as chemoinfusion, chemoembolization or selective internal radiation with Yttrium 90 radioembolization. The purpose of this review is to describe the different interventional therapies that are available for these patients in routine clinical practice, the most important clinical trials that have tried to demonstrate the effectiveness of each therapy and recommendations from principal medical oncologic societies.

show abstract

Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

Cited by 80 publications

References 112 publications

Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey

Attitudes of Canadian Colorectal Cancer Care Providers towards Liver Transplantation for Colorectal Liver Metastases: A National Survey

Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors

Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist

Contact Info

Product

Resources

About